Summary
Conclusion
In our series of 81 cases, a history of family cancer was present in 52% of patients (42/81) with pancreatic cancer. Nine percent (7/81) had a family history of pancreatic cancer. Our studies suggest a possible relationship of family cancer history to the expression of p53 and p21 WAF in pancreatic tumors, but show no relationship to the expression of HER-2/neuor to the prevalence of K-ras mutations. A lower incidence of p53 expression observed in patients with a family history of cancer suggests normal p53 protein is present in a majority of patients who develop pancreatic tumors related to other—as yet unidentified-inherited or familial risk factors. There was no significant difference in survival of pancreas cancer patients with and without a family history of cancer. However, survival in pancreas cancer patients may be influenced (improved) by p21WAF-1 expression.
Background
Pancreas cancer is the fifth leading cause of cancer deaths (27,800 deaths/yr) in the United States. Various risk factors, including cigaret smoking, high-fat diet, DDT exposure, chronic pancreatitis, and diabetes mellitus, have been associated with pancreatic carcinoma. A few studies have suggested a genetic predisposition or increased risk for pancreatic cancer within families, but the exact etiology is largely unknown. In a series of 81 patients with pancreatic carcinoma, we analyzed the status of K-ras gene mutations and the expression of P21WAF-1, p53, and HER-2/neu protein to identify possible molecular associations in pancreas cancer cases of these molecular markers to family histories of cancer and pancreas cancer.
Methods
Paraffin-embedded tissue sections from 81 cases of pancreatic adenocarcinoma were used for DNA extraction and immunohistochemical staining. K-ras mutation was studied by single-stranded conformation polymorphism (SSCP) and slot-blot allele-specific oligonucleotide (ASO) hybridization of PCR-amplified DNA product. Overexpression (aberrant expression) of p53, p21WAF-1, and HER-2/neu was documented by scoring nuclear localized p53 and p21WAF-1 protein and cell membrane expression of HER-2/neu after immunostaining with gene product-specific monoclonal antibodies (MAbs).
Results
Forty-two (42) of 81 patients studied in this series had a history of cancer in their families (52%). Seven of those 42 had a history of pancreatic carcinoma (17%, or 9% of total cases). The incidence of K-ras mutation and the expression of p21WAF-1 and HER-2/neu in patient groups with and without a family history of cancer was not statistically different (83 vs 74%,p=0.416; 57 vs 41%,p=0.184; and 83 vs 81%,p=1.000, respectively). However, the incidence of p53 expression was significantly lower in patients with a family history of cancer (40 vs 72%,p=0.007). there was no statistical difference in survival of patients with a family history of cancer in relation to either K-ras mutation, p53 expression, p21, or HER-2/neu expression. However, patients lacking a family history of cancer showed improved survival trends in relation to p21 expression (median survival of 16 vs 8 mo,p=0.029).
Similar content being viewed by others
References
Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996.CA Cancer J Clin 1996; 65: 5–27.
Falk RT, Pickle LW, Fontham ET, et al. Life-style risk factors for pancreatic cancer in Louisiana: a case-control study.Am J Epidemiol 1988; 128: 324–336.
Norell SE, Ahlbom A, Erwald R, et al. Diet and pancreatic cancer: a case-control study.Am J Epidemiol 1986; 124: 894–902.
Garabrant DH, Held J, Langholz M, Peters JM, Mack TM. DDT and related compounds and risk of pancreatic cancer.JNCI 1992; 84: 764–771.
Mack TM, Yu MC, Hanish R, et al. Pancreas cancer and smoking, beverage consumption, and past medical history.JNCI 1986; 76: 49–60.
Gordis L. Consumption of methylxanthine-containing beverages and risk of pancreatic cancer.Cancer Lett 1990; 52: 1–12.
Cuzick J, Babiker AG. Pancreatic cancer, alcohol, diabetes mellitus and gallbladder disease.Int J Cancer 1989; 43: 415–421.
Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer.N Engl J Med 1993; 328: 1433–1437.
Evans JP, Burke W, Chen R, Bennett RL, Schmidt RA, Dellinger EP, Kimmey M, Crispin D, Brentnall TA, Byrd DR. Familial pancreatic adenocarcinoma: association with diabetes and early molecular diagnosis.J Med Genet 1995; 32: 330–335.
Mulvihill JJ, Miller RW, Fraumeni JF, eds.Genetics Repertory of Human Neoplasia. Raven, New York 1977; pp. 137–143.
Watson P, Lynch HT. Extracolonic cancer in HNPCC.Cancer 1993; 71: 677–685.
Castleman B. Case 25, case records of the Massachusetts General Hospital.N Engl J Med 1972; 286: 1353–1359.
Raimer RR, Fraumeni JF, Ozols RF, et al. Pancreatic cancer in father and son.Lancet 1977; 1: 911, 912.
Ehrenthal D, Haeger L, Griffin T, Compton C. Familial pancreatic adenocarcinoma in three generations.Cancer 1987; 59: 1661–1664.
Danes BS, Lynch HT. A familial aggregation of pancreatic cancer. An in vitro study.JAMA 1982; 247: 2798–2802.
Ghadirian P, Simard A, Baillargeon J. Family aggregation of pancreatic cancer: a population-based case-control study.Proc Am Assoc Cancer Res 1988; 29: 257.
Lynch HT, Fitzsimmonds RN, Smyrk TC, et al. Familial pancreatic cancer: clinicopathologic study of 18 nuclear families.Am J Gastroenterol 1990; 85: 54–60.
Johannsson C, Ostermeyer EA, Hakansson S, Friedman LS, Johansson U, Sellberg G, Brondum-Nielsen K, Sele V, Olsson H, King M-C, Borg A. Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.Am J Hum Genet 1996; 58: 441–450.
Ghadirian P, Cadotte M, Lacroix A, Baillarqeon J, Perret C. Colon cancer in seven siblings.Eur J Cancer 1993; 29A (11): 1553–1556.
Liu L, Lassam NJ, Slingerland JM, Bailey D, Cole D, Jenkins R, Hogg D. Germline p16INK4 mutation and protein dysfunction in a family with inherited melanoma.Oncogene 1995; 11 (2): 405–412.
Sarkar FH, Valdivieso M, Borders J, Yao K-L, Raval MT, Madan SK, Sreepathi P, Shimoyama R, Steiger Z, Visscher DW, Crissman JD. A universal method for the mutational analysis of K-and p53 gene in non-small-cell lung cancer using formalin-fixed paraffin-embedded tissue.Diagn Mol Pathol 1995; 4 (4): 266–273.
Chen YQ, Cipriano SC, Sarkar FH, Ware JL, Arenkiel JM. p53-independent induction of p21 (WAF-1) pathway is preserved during tumor progression.Int J Oncol 1995; 7: 889–893.
Levine AJ. The tumor suppressor genes.Ann Rev Biochem 1993; 62: 623–651.
Li FP, Fraumeni JF Jr, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds.Cancer Res 1988; 48: 5358–5362.
Birch JM, Hardey AL, Tricker KJ, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-fraumeni families.Cancer Res 1994; 54: 1298–1304.
Selvakumaran M, Lin HK, Miyashita T, Wang HG, Krajewski S, Reed JC, Hoffman B, Liebermann D. Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways.Oncogenes 1994; 9: 1791–1798.
Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC. Tumor suppressor p53 is a regulator of bcl-2 and hex gene expression in vitro and in vivo.Oncogene 1994; 9: 1799–1805.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dergham, S.T., Dugan, M.C., Arlauskas, P. et al. Relationship of family cancer history to the expression of P53, P21WAF-1, HER-2/neu, and K-ras mutation in pancreatic adenocarcinoma. Int J Gastrointest Canc 21, 225–234 (1997). https://doi.org/10.1007/BF02821608
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02821608